Previous 10 | Next 10 |
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a firesi...
Summary Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 2022. A good pipeline allows us to assume high growth in the coming years. ...
Summary Today, we take our first look at a developmental company called Vaxcyte. The stock has had a huge rally since quite promising results from a Phase 1/2 clinical study around its primary pipeline candidate were posted in late October. What next for this vaccine concern? A...
Vaxcyte ( NASDAQ: PCVX ) on Thursday said the U.S. Food and Drug Administration (FDA) had granted a breakthrough therapy designation to its pneumococcal conjugate vaccine (PCV) candidate VAX-24. The company said the FDA's decision was based on results from an early-to-mid stage pr...
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity ...
Vaxcyte press release ( NASDAQ: PCVX ): Q3 GAAP EPS of -$0.93 misses by $0.09 . For further details see: Vaxcyte GAAP EPS of -$0.93 misses by $0.09
-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safet...
Summary Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects. Vaxcyte's lead candidate, VAX-24, is believed to be a potential pneumococcal conjugate vaccine. Since the start of the year, bearish sentiment has ...
Shares of Vaxcyte (NASDAQ: PCVX) , a clinical-stage vaccine innovation company, climbed 110.70% this week, according to data from S&P Global Intelligence . The stock closed last week at $20.58. It then opened dramatically higher on Monday at $35.15 and climbed to a weekly an...
SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underw...
News, Short Squeeze, Breakout and More Instantly...
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Boa...
2024-06-23 20:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...